person · Reporting owner

ACKERMANN CHRISTINA

Disclosed activity across 4 companies

Tapewire entity: 74410
SEC CIK: 0001681871

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bausch & Lomb CorpBLCO · Entity 3756	Please see remarks	March 01, 2023	March 03, 2023
Bausch Health Companies Inc.BHC · Entity 4363	EVP AND GENERAL COUNSEL	March 10, 2022	March 11, 2022
CalciMedica, Inc.GRAY · Entity 7804	Director	March 23, 2023	March 27, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bausch & Lomb Corp

Report date March 01, 2023 · Filed March 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, No Par ValueSEC Table I · non-derivative	Direct	146,677	Reported balance After 2023-03-01 transaction · row 1 1 source row Row 1 · 2023-03-01 · Grant · Acquired 28,344 · Balance 146,677 F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation.
Non-Qualified Stock Options (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96	Direct	90,744	Reported balance After 2023-03-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-01 · Grant · Acquired 90,744 · Balance 90,744 F2: Reflects the grant of stock options to purchase Common Shares under the Plan. F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4: The stock options will expire on the tenth anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation.

F2: Reflects the grant of stock options to purchase Common Shares under the Plan.

F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement.

F4: The stock options will expire on the tenth anniversary of the grant date.

Bausch Health Companies Inc.

Report date March 10, 2022 · Filed March 11, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, No Par ValueSEC Table I · non-derivative	Direct	162,240	Reported balance After 2022-03-10 transaction · row 1 1 source row Row 1 · 2022-03-10 · Tax withholding · Disposed 839 · Balance 162,240 F1: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

Filing footnotes · ownership attribution and instrument terms

F1: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

CalciMedica, Inc.

Report date March 23, 2023 · Filed March 27, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,429	Reported balance After 2023-03-23 transaction · row 1 1 source row Row 1 · 2023-03-23 · Disposition to issuer · Acquired 1,429 · Balance 1,429 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-03-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-23 · Disposition to issuer · Disposed 1,429 · Balance 0 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Verona Pharma plc

Report date October 07, 2025 · Filed October 08, 2025

Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Last balance in matching sequence After 2025-10-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2025-10-07 · Disposition to issuer · Disposed 64,072 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
Restricted Share UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28	Direct	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2033-08-31	Direct	Reported balance After 2025-10-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-10-07 · Disposition to issuer · Disposed 144,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 07, 2025 Filed Oct 8, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Disposition to issuerShare Options (Right to Buy) · Derivative	144,000	Not disclosed Strike: $2.43	Not disclosed	Disclosure SEC source: 0001104659-25-097941 · tm2528014-1_4seq1.xml · derivative · entry 6 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 144,000 shares Expires 2033-08-31 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Disposition to issuerShare Options (Right to Buy) · Derivative	200,000	Not disclosed Strike: $1.93	Not disclosed	Disclosure SEC source: 0001104659-25-097941 · tm2528014-1_4seq1.xml · derivative · entry 5 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 200,000 shares Expires 2034-04-28 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Exercise / conversionRestricted Share Unit · Derivative	72,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-097941 · tm2528014-1_4seq1.xml · derivative · entry 4 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 72,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4 · derivative.exercise_price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Disposition to issuerOrdinary Shares	72,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-097941 · tm2528014-1_4seq1.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Exercise / conversionOrdinary Shares	72,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-097941 · tm2528014-1_4seq1.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Disposition to issuerOrdinary Shares	64,072	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-097941 · tm2528014-1_4seq1.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · price: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3 · price: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Read SEC document
August 01, 2025 Filed Aug 5, 2025 20:26 UTC	Verona Pharma plc VRNA · Entity 74409	Exercise / conversionRestricted Stock Units · Derivative	24,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-074396 · tm2522566-9_4seq1.xml · derivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Ordinary Shares · 24,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F5 · derivative.exercise_price: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
August 01, 2025 Filed Aug 5, 2025 20:26 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	1,808	$13.14	$23,763.81	Disclosure SEC source: 0001104659-25-074396 · tm2522566-9_4seq1.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,072 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the Reporting Person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs"). F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of 64,072 Ordinary Shares represented by 8,009 ADSs. Read SEC document
August 01, 2025 Filed Aug 5, 2025 20:26 UTC	Verona Pharma plc VRNA · Entity 74409	Exercise / conversionOrdinary Shares	24,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-074396 · tm2522566-9_4seq1.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
May 14, 2025 Filed May 16, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Exercise / conversionShare Options (Right to Buy) · Derivative	40,000	$0.00 Strike: $1.93	$0.00	Disclosure SEC source: 0001104659-25-050043 · tm2515382-1_4seq1.xml · derivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 40,000 shares Expires 2034-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F5 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F6 · derivative.exercise_date: The option is fully vested. F5 · derivative.underlying: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
May 14, 2025 Filed May 16, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	40,000	$8.44	$337,600.00	Disclosure SEC source: 0001104659-25-050043 · tm2515382-1_4seq1.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,880 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into on February 12, 2025. F3 · price: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $8.3894 to $8.5688 per Ordinary Share, inclusive (or $67.115 to $68.55 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · balance_after: Consists of 41,880 Ordinary Shares represented by 5,235 ADSs. Read SEC document
May 14, 2025 Filed May 16, 2025 16:30 UTC	Verona Pharma plc VRNA · Entity 74409	Exercise / conversionOrdinary Shares	40,000	$1.93	$77,352.00	Disclosure SEC source: 0001104659-25-050043 · tm2515382-1_4seq1.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
April 25, 2025 Filed Apr 29, 2025 17:08 UTC	Verona Pharma plc VRNA · Entity 74409	GrantRestricted Share Units · Derivative	96,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-041382 · tm2513544-1_4seq1.xml · derivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Ordinary Shares · 96,000 shares Expires not disclosed F1 · security: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.exercise_price: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · shares: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F2 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Read SEC document
November 06, 2024 Filed Nov 7, 2024 18:56 UTC	Verona Pharma plc VRNA · Entity 74409	PurchaseOrdinary Shares	41,880	$4.74	$198,385.56	Disclosure SEC source: 0001104659-24-115417 · tm2427856-1_4seq1.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,880 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · balance_after: Consists of 41,880 Ordinary Shares represented by 5,235 ADSs. Read SEC document
April 29, 2024 Filed Apr 30, 2024 16:17 UTC	Verona Pharma plc VRNA · Entity 74409	GrantShare Options (Right to Buy) · Derivative	240,000	$0.00 Strike: $1.93	$0.00	Disclosure SEC source: 0001104659-24-054951 · tm2412993-3_4seq1.xml · derivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Ordinary Shares · 240,000 shares Expires 2034-04-28 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:05 UTC	Verona Pharma plc VRNA · Entity 74409	GrantShare Options (Right to Buy) · Derivative	144,000	$0.00 Strike: $2.43	$0.00	Disclosure SEC source: 0001104659-23-098231 · tm2325478-2_4seq1.xml · derivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Ordinary Shares · 144,000 shares Expires 2033-08-31 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to one-third of the underlying options on September 1, 2024 and the remainder in eight equal quarterly installments over the two years thereafter. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
March 23, 2023 Filed Mar 27, 2023 23:54 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerRestricted Stock Unit · Derivative	1,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021297 · doc4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.exercise_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.expiration_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
March 23, 2023 Filed Mar 27, 2023 23:54 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerCommon Stock	1,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021297 · doc4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429 F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Christina Ackermann's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:55 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantNon-Qualified Stock Options (right to purchase) · Derivative	90,744	$17.96 Strike: $17.96	$1,629,762.24	Disclosure SEC source: 0001127602-23-008771 · form4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · Please see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,744 Underlying: Common Shares, No Par Value · 90,744 shares Expires not disclosed F2 · shares: Reflects the grant of stock options to purchase Common Shares under the Plan. F3 · derivative.exercise_date: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4 · derivative.expiration_date: The stock options will expire on the tenth anniversary of the grant date. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:55 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	28,344	$0.00	$0.00	Disclosure SEC source: 0001127602-23-008771 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Please see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,677 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation. Read SEC document
July 25, 2022 Filed Jul 27, 2022 23:38 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	35,000	$0.00	$0.00	Disclosure SEC source: 0001127602-22-019824 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Please see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,333 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation. Read SEC document
June 02, 2022 Filed Jun 3, 2022 21:31 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantRestricted Stock Units · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034247 · doc4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock, subject to the reporting person's continued status as a service provider to the issuer. F1 · derivative.exercise_date: The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. F3 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document
June 02, 2022 Filed Jun 3, 2022 21:31 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.98	$0.00	Disclosure SEC source: 0001209191-22-034247 · doc4.xml · derivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
May 05, 2022 Filed May 9, 2022 22:46 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantNon-Qualified Stock Options (right to purchase) · Derivative	329,670	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0000899243-22-017321 · doc4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · Please see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,670 Underlying: Common Shares, No Par Value · 329,670 shares Expires not disclosed F2 · shares: Reflects the grant of stock options to purchase Common Shares under the Plan. F3 · derivative.exercise_date: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4 · derivative.expiration_date: The stock options will expire on the tenth anniversary of the grant date. Read SEC document
May 05, 2022 Filed May 9, 2022 22:46 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	83,333	$0.00	$0.00	Disclosure SEC source: 0000899243-22-017321 · doc4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Please see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation (the "Company"). Read SEC document
March 10, 2022 Filed Mar 11, 2022 21:00 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	839	$22.56	$18,927.84	Disclosure SEC source: 0001127602-22-009006 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,240 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document
March 03, 2022 Filed Mar 7, 2022 22:45 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	6,926	$23.61	$163,522.86	Disclosure SEC source: 0001127602-22-008496 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,079 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document
February 27, 2022 Filed Mar 3, 2022 02:06 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionRestricted Share Units · Derivative	24,292	$24.35 Strike: $24.35	$591,510.20	Disclosure SEC source: 0000899243-22-008818 · doc4.xml · derivative · entry 6 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 24,292 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document
February 27, 2022 Filed Mar 3, 2022 02:06 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	3,006	$24.35	$73,196.10	Disclosure SEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 4 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,005 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document
February 27, 2022 Filed Mar 3, 2022 02:06 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	2,743	$24.35	$66,792.05	Disclosure SEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,011 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document
February 27, 2022 Filed Mar 3, 2022 02:06 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	10,279	$24.35	$250,293.65	Disclosure SEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,754 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document
February 27, 2022 Filed Mar 3, 2022 02:06 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionCommon Shares, No Par Value	24,292	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document
February 14, 2022 Filed Mar 3, 2022 02:06 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantRestricted Share Units · Derivative	24,292	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-008818 · doc4.xml · derivative · entry 5 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 24,292 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document
August 27, 2021 Filed Aug 31, 2021 20:07 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	5,017	$28.95	$145,242.15	Disclosure SEC source: 0001127602-21-024579 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,741 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:51 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionNon-Qualified Stock Options (right to purchase) · Derivative	60,853	$0.00 Strike: $15.32	$0.00	Disclosure SEC source: 0001127602-21-019273 · form4.xml · derivative · entry 5 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 60,853 shares Expires 2028-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:51 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionNon-Qualified Stock Options (right to purchase) · Derivative	60,345	$0.00 Strike: $14.38	$0.00	Disclosure SEC source: 0001127602-21-019273 · form4.xml · derivative · entry 4 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 60,345 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:51 UTC	Bausch Health Companies Inc. BHC · Entity 4363	SaleCommon Shares, No Par Value	121,198	$31.83	$3,857,732.34	Disclosure SEC source: 0001127602-21-019273 · form4.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,758 F1 · price: The price in Column 4 reflects the average weighted sale price for the transactions aggregated on this Form 4. The sales price per share reported on this Form 4 range from $31.61 to $32.11. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:51 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionCommon Shares, No Par Value	60,853	$15.32	$932,267.96	Disclosure SEC source: 0001127602-21-019273 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:51 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionCommon Shares, No Par Value	60,345	$14.38	$867,761.10	Disclosure SEC source: 0001127602-21-019273 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 02, 2021 Filed Jun 4, 2021 22:30 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantEmployee Stock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $4.07	$0.00	Disclosure SEC source: 0001209191-21-038372 · doc4.xml · derivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-01 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
March 11, 2021 Filed Mar 15, 2021 20:08 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	796	$32.82	$26,124.72	Disclosure SEC source: 0001127602-21-010592 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,758 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document
March 10, 2021 Filed Mar 11, 2021 01:46 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	21,960	$32.97	$724,021.20	Disclosure SEC source: 0001127602-21-010158 · form4.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,554 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs and RSUs. Read SEC document
March 08, 2021 Filed Mar 11, 2021 01:46 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionRestricted Share Units · Derivative	8,455	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-010158 · form4.xml · derivative · entry 4 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,455 shares Expires 2021-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. F4 · derivative.exercise_date: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics. F4 · derivative.expiration_date: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on March 9, 2018 with the maximum potential award amount of 13,638 shares. Any portion of the award not vested as of the transaction date was cancelled as of that date. Read SEC document
March 08, 2021 Filed Mar 11, 2021 01:46 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantCommon Shares, No Par Value	25,980	$0.00	$0.00	Disclosure SEC source: 0001127602-21-010158 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,514 F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. Read SEC document
March 08, 2021 Filed Mar 11, 2021 01:46 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionCommon Shares, No Par Value	8,455	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-010158 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document
March 03, 2021 Filed Mar 5, 2021 22:45 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantNon-qualified Stock Options (right To Purchase) · Derivative	52,392	$0.00 Strike: $32.56	$0.00	Disclosure SEC source: 0001127602-21-009554 · form4.xml · derivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,392 Underlying: Common Shares, No Par Value · 52,392 shares Expires 2031-03-03 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document
March 03, 2021 Filed Mar 5, 2021 22:45 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantCommon Shares, No Par Value	36,250	$0.00	$0.00	Disclosure SEC source: 0001127602-21-009554 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,079 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc. Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:26 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	5,367	$31.42	$168,631.14	Disclosure SEC source: 0001127602-21-009134 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,829 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document
September 24, 2020 Filed Sep 28, 2020 21:37 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantDirector Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-20-052238 · doc4.xml · derivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-23 F1 · derivative.exercise_date: The option shall vest as to 1/36th of the total shares on October 24, 2020 and on each monthly anniversary thereafter such that the option shall be fully vested on September 24, 2023, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document
August 28, 2020 Filed Aug 31, 2020 22:44 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantCommon Shares, No Par Value	28,171	$0.00	$0.00	Disclosure SEC source: 0001127602-20-024485 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,196 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.